Atypical hyperplasia of the breast

3 imperatives to transform health care in America. You're invited to watch it live

Free

E-newsletter

Subscribe to Housecall

Our weekly general interest
e-newsletter keeps you up to date on a wide variety of health topics.

Sign up now

Tests and diagnosis

By Mayo Clinic staff

Living With Cancer

Subscribe to our Living With Cancer e-newsletter to stay up to date on cancer topics.

Sign up now

Atypical hyperplasia is usually discovered after a biopsy to evaluate a suspicious area found on a mammogram or during a clinical breast exam. During the biopsy, tissue samples are removed and sent for analysis by a specially trained doctor (pathologist). The tissue samples are examined under a microscope, and the pathologist identifies atypical hyperplasia, if it's present.

To further evaluate atypical hyperplasia, your doctor may recommend surgery to remove a larger sample of tissue to look for breast cancer. A diagnosis of atypical hyperplasia may lead to a surgical biopsy (wide local excision or lumpectomy) to remove all of the affected tissue. The pathologist looks at the larger specimen for evidence of in situ or invasive cancer.

References
  1. Lester SC. The breast. In: Kumar V, et al. Robbins and Cotran Pathologic Basis of Disease. 8th ed. Philadelphia, Pa.: Saunders Elsevier; 2010. http://www.mdconsult.com/books/about.do?about=true&eid=4-u1.0-B978-1-4377-0792-2..X5001-9&isbn=978-1-4377-0792-2&uniqId=273803839-4. Accessed Aug. 17, 2011.
  2. Bombonati A, et al. The molecular pathology of breast cancer progression. Journal of Pathology. 2011;223:307.
  3. Hartmann LC, et al. Benign breast disease and the risk of breast cancer. The New England Journal of Medicine. 2005;353:229.
  4. London SJ, et al. A prospective study of benign breast disease and the risk of breast cancer. Journal of the American Medical Association. 1992;267:941.
  5. Degnim AC, et al. Stratification of breast cancer risk in women with atypia: A Mayo cohort study. Journal of Clinical Oncology. 2007;25:2671.
  6. Dupont WD, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993;71:1258.
  7. Breast cancer risk reduction. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Aug. 17, 2011.
  8. Breast cancer screening and diagnosis. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Aug. 17, 2011.
  9. Pruthi S (expert opinion). Mayo Clinic, Rochester, Minn. Aug. 31, 2011.
  10. Goss PE, et al. Exemestane for breast-cancer prevention in postmenopausal women. The New England Journal of Medicine. 2011;25:2381.
DS01018 Oct. 1, 2011

© 1998-2013 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.com," "EmbodyHealth," "Enhance your life," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.

  • Reprints
  • Print
  • Share on:

  • Email

Advertisement


Text Size: smaller largerlarger